| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 23.188.511 | 30.074.064 | 14.564.983 | 28.333.021 | 29.364.258 | 39.197.066 | 40.139.402 | 43.223.213 | 39.152.711 | 35.653.410 |
| Total Income - EUR | 23.742.161 | 31.281.813 | 17.436.157 | 26.605.000 | 31.303.108 | 40.974.616 | 41.765.019 | 52.526.418 | 39.086.725 | 34.726.466 |
| Total Expenses - EUR | 19.762.846 | 24.707.082 | 15.684.612 | 25.153.284 | 28.089.643 | 35.915.883 | 39.609.688 | 42.350.870 | 33.784.531 | 30.711.138 |
| Gross Profit/Loss - EUR | 3.979.314 | 6.574.732 | 1.751.545 | 1.451.715 | 3.213.465 | 5.058.732 | 2.155.331 | 10.175.547 | 5.302.194 | 4.015.328 |
| Net Profit/Loss - EUR | 3.415.181 | 5.664.630 | 1.586.001 | 1.315.076 | 2.862.818 | 4.443.577 | 2.012.493 | 9.081.310 | 4.707.279 | 3.485.086 |
| Employees | 157 | 164 | 171 | 187 | 193 | 151 | 172 | 220 | 237 | 236 |
Check the financial reports for the company - Fiterman Pharma Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 4.043.824 | 4.407.628 | 4.354.542 | 3.983.952 | 4.134.232 | 6.031.283 | 6.973.466 | 7.529.682 | 6.855.015 | 7.216.088 |
| Current Assets | 16.913.296 | 19.101.610 | 19.679.786 | 20.365.195 | 23.265.262 | 26.312.292 | 29.323.601 | 36.643.269 | 41.132.012 | 41.456.965 |
| Inventories | 3.932.846 | 4.394.365 | 7.485.644 | 5.741.873 | 7.366.316 | 9.660.565 | 13.535.666 | 16.556.893 | 14.531.277 | 12.855.514 |
| Receivables | 10.342.317 | 14.623.878 | 10.211.541 | 14.616.529 | 15.845.960 | 16.214.010 | 15.361.594 | 19.727.314 | 26.465.464 | 26.879.767 |
| Cash | 2.638.133 | 83.367 | 1.982.600 | 6.793 | 52.986 | 24.246 | 426.341 | 359.062 | 135.271 | 1.721.683 |
| Shareholders Funds | 13.565.432 | 17.902.147 | 17.791.200 | 17.542.545 | 18.890.681 | 21.731.816 | 21.526.816 | 23.196.620 | 25.626.638 | 26.775.492 |
| Social Capital | 13.723 | 13.583 | 13.353 | 13.108 | 12.855 | 12.611 | 12.331 | 12.369 | 12.332 | 12.263 |
| Debts | 7.414.829 | 5.633.062 | 6.273.868 | 6.836.520 | 8.568.313 | 9.854.600 | 14.057.738 | 21.058.119 | 22.300.943 | 20.571.049 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 1.128 | 1.121 | 11.081 | 161.550 | 1.499.074 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "2120 - 2120" | |||||||||
| CAEN Financial Year |
2120
|
|||||||||
Comments - Fiterman Pharma Srl